In late March 2020, Broad Institute rapidly converted our large-scale genomics facility into a center that can process SARS-CoV-2 tests. Working in partnership with the Commonwealth of Massachusetts, Massachusetts State Public Health Laboratory, and medical facilities in the Commonwealth, the Broad's CLIA-certified lab processes samples collected from patients in Massachusetts and beyond.

Our current capacity is 10,000 tests per day, with results typically being returned within 24 hours from receipt. We are working to further increase capacity.

This page shows the number of SARS-CoV-2 viral diagnostic tests processed at the Clinical Research Sequencing Platform (CRSP) at the Broad Institute of MIT and Harvard.

These numbers are updated during the course of the day as samples are completed at Broad. For details on the testing platform and for a description of how institutions send samples for processing, please see our COVID-19 Test Information website.
Total Tests Completed

137,981

since 3/25/2020
Positive Tests

19,019

14% of tests
Inconclusive Tests + Invalid Tests

1,314

1.0% of tests
Tests by Region

112,959

from MA (82%)

25,022

from out of state (18%)
The numbers will not match the daily reports from the State of Massachusetts for several reasons:
  • Results are reported to the organization that sent the sample to us for testing. The sending institution must then report the results to the Massachusetts Department of Public Health, together with individual demographic data it has collected.
  • A small number of people are tested more than once (for example, as a confirmation or re-test). The figures here reflect the number of tests performed, not the number of people tested. The State reports the number of people.
  • Broad Institute processes some tests from other states.
The "percent positive" pertains to the tests submitted to Broad. Because different organizations use different criteria for selecting individuals for testing, it is not possible to draw meaningful conclusions about infection rates or trends from these data.

The Clinical Research Sequencing Platform, LLC is a subsidiary of the Broad Institute.